Leading the Fight to treatand cure Tay-Sachs, Canavan and related diseases
Gene Therapy (TSGT) Consortium was formed in 2007 with the goal of initiating a gene therapy clinical trial for Tay-Sachs disease and Sandhoff disease. Read more about the TSGT Consortium results and progress toward a cure.
The TSGT Consortium includes scientists and clinicians from the following institutions:
The TSGT Consortium is led by Dr. Miguel Sena Esteves, recipient of the 2011 Outstanding New Investigator Award from the American Society of Gene & Cell Therapy. Often referred to as the “unit of heredity,” a gene is composed of a sequence of DNA required to produce a functional
Visit the TSGT website at www.tsgtconsortium.com to read about all the scientists and clinicians in the TSGT Consortium.
The TSGT Consortium seeks rapid development of the most effective gene therapy approach for the clinical trial. To accomplish this goal, they are pooling their resources and extensive experience in experimental gene therapy to devise the most effective adeno-associated virus (AAV)-based gene therapy approach for treating Tay-Sachs and Sandhoff disease.
National Tay-Sachs & Allied Diseases Association2001 Beacon StreetSuite 204Boston, MA 02135
email@example.com(617) 277-4463 phone(617) 277-0134 fax
At NTSAD, we are making a difference. Every day. Helping families and individuals find their way and providing hope by supporting research on many levels. All of this takes compassion and determination.
There is no time to waste, and families need our help. Those who are fighting today and those who will seek our help tomorrow.
Make a Gift
HomeAbout NTSADMission & VisionBoard of DirectorsStaff & ProfilesChapters & AffiliatesScientific Advisory CommitteeFinancialsOur HistoryNewsLibrary DocumentsGlossaryContactSearch